Berberine vs RAD-140
Moderate Research vs Emerging
avoid Mechanism-based · 53% Both Berberine and RAD-140 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.
Molecular Data
Berberine RAD-140
Weight 336.36 Da 393.83 Da
Half-life ~4 hours ~60 hours
Type Isoquinoline alkaloid (C20H18NO4+) Nonsteroidal selective androgen receptor modulator (C20H16ClN5O2)
Key Benefits
Berberine
01 Activation of AMPK, improving cellular energy metabolism and glucose utilization
02 Clinically demonstrated reductions in fasting blood glucose and HbA1c comparable to metformin in some trials
03 Improved lipid profiles with reductions in total cholesterol, LDL cholesterol, and triglycerides
04 Enhanced insulin sensitivity through upregulation of insulin receptor expression
05 PCSK9 inhibition leading to improved LDL cholesterol clearance
06 Gut microbiome modulation favoring beneficial short-chain fatty acid-producing bacteria
07 Anti-inflammatory effects via NF-kB pathway suppression
08 Available over the counter as a dietary supplement without prescription
RAD-140
01 Potent anabolic activity in muscle tissue with high oral bioavailability
02 Tissue-selective action sparing the prostate and other androgen-sensitive organs
03 No aromatization to estrogen (no estrogen-related side effects such as water retention or gynecomastia)
04 No conversion to DHT (reduced risk of hair loss and prostate stimulation compared to testosterone)
05 Long half-life (~60 hours) permitting convenient once-daily oral dosing
06 Neuroprotective properties observed in preclinical models
07 Increased lean body mass and reduced fat mass in preclinical studies
Side Effects
Berberine
Gastrointestinal distress (diarrhea, cramping, bloating, nausea, flatulence) - most frequent complaint, affecting 10-15% of users, especially at higher doses or without food
Constipation (less common than diarrhea but reported by some users)
Decreased appetite
Mild abdominal discomfort, particularly during the first 1-2 weeks of use
RAD-140
Testosterone suppression (dose-dependent, occurs in virtually all users by week 4-6)
Liver enzyme elevation (ALT, AST increases reported in clinical and anecdotal data)
Hair shedding (temporary, typically resolves after discontinuation)
Headaches (most common in the first 1-2 weeks, often transient)
Nausea (mild, usually with initial doses or on an empty stomach)
Lipid disruption (HDL suppression, LDL elevation)
Mild insomnia or sleep disturbance
Reduced libido and mood changes related to testosterone suppression
Contraindications
Pregnancy and breastfeeding (berberine may stimulate uterine contractions and crosses into breast milk)
Neonates and young children (risk of kernicterus - berberine can displace bilirubin from albumin)
Severe hepatic impairment
Concurrent use with medications that have narrow therapeutic indices metabolized by CYP3A4 (e.g., cyclosporine, tacrolimus) without close medical supervision
Known hypersensitivity to berberine or berberine-containing plants
Pre-existing liver disease or elevated liver enzymes at baseline
Hormone-sensitive cancers (prostate cancer, certain breast cancers not being treated under clinical supervision)
Pregnancy or potential pregnancy (teratogenic risk from androgen receptor agonism)
Breastfeeding
Age under 25 (incomplete endocrine system maturation and higher risk of HPG axis disruption)
Concurrent use of hepatotoxic medications without medical supervision
Known cardiovascular disease (insufficient safety data for this population)
Research Evidence
Berberine RAD-140
Status Moderate Research Emerging
References 5 studies 5 studies
Latest 2023 July 2020
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.